Date Title Description PDF
25 Apr 2023 On business and financial situation ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) Download
21 Feb 2023 On business and financial situation The Company releases the press release related to the full year 2022 financial results. Download
21 Feb 2023 On business and financial situation The company releases the Integrated Report for the year 2022 Download
21 Feb 2023 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download
21 Feb 2023 On business and financial situation The Company releases the full year 2022 financial results presentation. Download

Pages

Date Title Description PDF
21 Oct 2021 Liquidity and counterparty agreements Download
21 Oct 2021 On business and financial situation The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). Download
07 Oct 2021 Liquidity and counterparty agreements Download
04 Oct 2021 Liquidity and counterparty agreements Download
01 Sep 2021 On business and financial situation ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine Download

Pages

Date Title Description PDF
26 Jul 2018 Información sobre resultados ROVI releases the press release related to the 2018 first half financial results Download
02 Jul 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the second quarter of 2018 Download
22 Jun 2018 Información sobre dividendos The Company informs about the dividends payment Download
12 Jun 2018 Otros sobre negocio y situación financiera Corporate presentation update Download
29 May 2018 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its General Shareholders Meeting Download

Pages